GBY Stock Overview
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sangamo Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.56 |
52 Week High | US$1.62 |
52 Week Low | US$0.26 |
Beta | 1.44 |
1 Month Change | -49.17% |
3 Month Change | 11.33% |
1 Year Change | -62.86% |
3 Year Change | -94.79% |
5 Year Change | -94.71% |
Change since IPO | -94.91% |
Recent News & Updates
Recent updates
Shareholder Returns
GBY | DE Biotechs | DE Market | |
---|---|---|---|
7D | -32.9% | 1.2% | 2.5% |
1Y | -62.9% | 34.7% | 7.0% |
Return vs Industry: GBY underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: GBY underperformed the German Market which returned 7.3% over the past year.
Price Volatility
GBY volatility | |
---|---|
GBY Average Weekly Movement | 40.5% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GBY's share price has been volatile over the past 3 months.
Volatility Over Time: GBY's weekly volatility has increased from 26% to 40% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 405 | Sandy Macrae | https://www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. Fundamentals Summary
GBY fundamental statistics | |
---|---|
Market cap | €117.52m |
Earnings (TTM) | -€238.16m |
Revenue (TTM) | €162.79m |
0.7x
P/S Ratio-0.5x
P/E RatioIs GBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GBY income statement (TTM) | |
---|---|
Revenue | US$176.23m |
Cost of Revenue | US$221.56m |
Gross Profit | -US$45.32m |
Other Expenses | US$212.51m |
Earnings | -US$257.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.27 |
Gross Margin | -25.72% |
Net Profit Margin | -146.30% |
Debt/Equity Ratio | 0% |
How did GBY perform over the long term?
See historical performance and comparison